T2 Biosystems Highlights Current and Future Opportunities for its Breakthrough Rapid Diagnostic Technology for Biothreat Pat...
June 17 2019 - 7:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the
development of innovative medical diagnostic products for critical
unmet needs in healthcare, announced today that the Company will
present new data regarding the potential of its technology to be
used for the rapid detection of biothreat pathogens during the
Fifth Annual Biodefense World Summit 2019, taking place June 17 –
19 in Bethesda, MD.
The presentation, A Rapid, Direct-from-Blood Diagnostic to
Address Infections from Multidrug Resistant Organisms (MDROs), will
take place on Monday, June 17 at 12:00 pm and will feature Tom
Lowery, PhD, chief scientific officer, T2 Biosystems. During the
presentation, Dr. Lowery will highlight how rapid,
direct-from-blood diagnostics – such as the T2Bacteria®,
T2Candida® and T2Resistance™ Panels – can help slow the spread
of MDROs and improve patient outcomes. Dr. Lowery will also
highlight new data supporting potential future uses of the T2MR®
technology for biodefense applications.
During the presentation, Dr. Lowery will share a number of
updates on the clinical utility of T2 technology that further prove
T2MR’s ability to enable high-sensitivity, blood
culture-independent detection of pathogens at ultra-high
sensitivity, including:
- T2Bacteria provides actionable clinical
information: New independent T2Bacteria Panel clinical
data demonstrates its ability to substantially benefit patients
suspected of sepsis in both the emergency department and intensive
care unit by providing information that enables significant
reductions in time to effective therapy, de-escalation of
unnecessary therapy, and avoidance of premature discharges and
readmissions to the emergency department.
- T2Candida auris research-use-only provides
significantly faster results in detecting the recently emerging
superbug, Candida auris: Research data shows that the
T2Candida auris RUO Panel can detect all four known clades of
Candida auris in 5 hours, compared to 14 days with culture
methods.
- T2Lyme clinical performance: T2Lyme clinical
accuracy data show T2Lyme has higher accuracy than any of the
currently available methods and higher positivity rate than
existing PCR methods.
- T2MR Technology can detect five biothreat
pathogens: New data show that the T2MR technology can
detect five biothreat pathogens, including: Bacillus anthracis
(anthrax), Burkholderia spp., Rickettsia prowazekii, Francisella
tularensis and Yersinia pestis. These biothreat pathogens can be
detected by T2MR technology, which has been proven to work in whole
blood (no pre-culture required), environmental samples, other
biofluids, and swab samples. The Department of Homeland Security
(DHS) has defined these as biothreat pathogens because they require
quick antibiotic treatment and can be difficult to diagnose due to
non-distinguishing symptoms, making the development and
availability of rapid, high-throughput, high sensitivity
diagnostics for these biothreat pathogens a national priority.
“Like so many of our peers at this year’s Biodefense World
Summit, we are increasingly concerned by the serious public health
threat posed by MDROs on a global scale,” said John McDonough,
president and chief executive officer of T2 Biosystems. “Our unique
technology is a proven weapon in the fight against the spread of
these dangerous biological agents, providing earlier detection and
reducing the unnecessary use of inappropriate antibiotic therapy,
which is a driver of drug-resistance in these organisms. We also
are excited with the potential to expand our technology for the
detection of Candia auris, which is already available as a
research-use-only product, and other pathogens that are relevant to
the field of biodefense.”
T2 Biosystems is the company behind the T2Bacteria Panel, the
first and only FDA-cleared test to identify sepsis-causing
bacterial pathogens directly from whole-blood in 3 to 5 hours
without the wait for blood culture, enabling patients to be placed
on targeted therapy faster, improving those patients’ outcomes. The
T2Bacteria Panel is one of several panels that are approved or in
development that are run on the Company’s T2Dx® Instrument, which
is powered by miniaturized magnetic resonance (T2MR)
technology.
About T2 Biosystems T2 Biosystems, a
leader in the development and commercialization of innovative
medical diagnostic products for critical unmet needs in healthcare,
is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than
ever before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, and T2Bacteria® Panel and are powered by the
proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems
has an active pipeline of future products, including products for
the detection of additional species and antibiotic resistance
markers of sepsis pathogens, and tests for Lyme disease.
Media Contact: Gina Kent, Vault
Communications gkent@vaultcommunications.com 610-455-2763
Investor Contact: Zack Kubow, W2O Group
zkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024